Status:
COMPLETED
Hypofractionated Radiotherapy for Recurrent DIPG
Lead Sponsor:
University of Cincinnati
Collaborating Sponsors:
Children's Hospital Medical Center, Cincinnati
Conditions:
Recurrent Diffuse Intrinsic Pontine Glioma
Eligibility:
All Genders
Up to 30 years
Phase:
NA
Brief Summary
This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fracti...
Eligibility Criteria
Inclusion
- Patients must be ≤30 years of age
- Patients must have a diagnosis of progressive DIPG.
- Received prior IMRT based definitive radiotherapy to a dose of ≥54 Gy.
- The patient and or parent/legal guardian must be physically and mentally capable of signing the consent form of their own volition.
- Steroids dosage must be unchanged for 5 days.
- No Bevacizumab within 21 days (Half-life 11 days \~)
Exclusion
- Patients with incomplete medical records
- Patients with prior history of reirradiation for DIPG
- Life expectancy \< or equal to 1 month
- Pregnant women
- Age \>30
- Prisoners
- Concurrent systemic therapy at the time of reirradiation
- Physically or mentally incapable of signing the consent form of their own volition
- \< 6 mos time interval between completion of initial RT to start of reRT.
Key Trial Info
Start Date :
January 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT03841435
Start Date
January 31 2018
End Date
March 3 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati
Cincinnati, Ohio, United States, 45267